KALA BIO, Inc. — Director's Dealing 2019

Oct 15, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2019-10-12

Reporting Person: Bazemore Todd (Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-10-12	Stock Option (right to buy)	$3.45	A	175000	Acquired	2029-10-11	Common Stock (175000)	Direct

Footnotes

F1: This option vests as to 2.0833% of the shares underlying the option on November 15, 2019 and as to an additional 2.0833% of the shares underlying the option at the end of each successive one month period thereafter.